FDA approves Allergan’s migraine tablet ahead of AbbVie mergerAllergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with Share XFDA approves Allergan’s migraine tablet ahead of AbbVie mergerhttps://pharmaphorum.com/news/fda-approves-allergans-migraine-tablet-ahead-of-abbvie-merger/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
Amgen, Allergan join Rituxan biosimilar challenge with FDA filingAmgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the Share XAmgen, Allergan join Rituxan biosimilar challenge with FDA filinghttps://pharmaphorum.com/news/amgen-allergan-join-rituxan-biosimilar-challenge-with-fda-filing/
Allergan builds case for migraine drug ubrogepant as FDA verdict nearsAllergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share XAllergan builds case for migraine drug ubrogepant as FDA verdict nearshttps://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/
Allergan bolsters aesthetics pipeline with Exicure hair loss dealAllergan hasn’t pressed pause on business development in the build-up to its $63 billion buyout by AbbVie, and Share XAllergan bolsters aesthetics pipeline with Exicure hair loss dealhttps://pharmaphorum.com/news/allergan-bolsters-aesthetics-unit-with-exicure-hair-loss-deal/
Allergan pays $750m to avoid Alzheimer’s drug lawsuitAllergan has agreed to pay $750 million to settle lawsuits in the US brought by direct purchasers of Share XAllergan pays $750m to avoid Alzheimer’s drug lawsuithttps://pharmaphorum.com/news/allergan-pays-750m-to-avoid-alzheimers-drug-lawsuit/
Allergan gets FDA okay for paediatric Botox useThe FDA has approved Allergan’s Botox to treat lower-limb spasticity in children, further extending the use of the Share XAllergan gets FDA okay for paediatric Botox usehttps://pharmaphorum.com/news/allergan-gets-fda-okay-for-paediatric-botox-use/
Unions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerUS antitrust authorities are coming under pressure from consumer groups and unions to block the proposed $63 billion Share XUnions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerhttps://pharmaphorum.com/news/unions-call-on-us-antitrust-regulators-to-block-63-billion-abbviegan-merger/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
